Immunovia AB (publ) (IMMNOV.ST)
SEK 0.28
(3.38%)
SEK 0.28
(3.38%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -309.43 Million SEK | -113.36% |
| 2022 | -145.03 Million SEK | 7.86% |
| 2021 | -157.39 Million SEK | -6.75% |
| 2020 | -147.45 Million SEK | -28.75% |
| 2019 | -114.52 Million SEK | -32.34% |
| 2018 | -86.53 Million SEK | -91.32% |
| 2017 | -45.23 Million SEK | -207.22% |
| 2016 | -14.72 Million SEK | -99.4% |
| 2015 | -7.38 Million SEK | 16.65% |
| 2014 | -8.85 Million SEK | -454.94% |
| 2013 | -1.59 Million SEK | -516.6% |
| 2012 | -258.9 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -2.94 Million SEK | 93.99% |
| 2024 Q2 | -25.59 Million SEK | -768.87% |
| 2023 FY | -309.43 Million SEK | -113.36% |
| 2023 Q2 | -170.2 Million SEK | -213.83% |
| 2023 Q1 | -54.23 Million SEK | 35.1% |
| 2023 Q3 | -38.55 Million SEK | 77.35% |
| 2023 Q4 | -49.02 Million SEK | -27.14% |
| 2022 Q3 | -3.94 Million SEK | 76.31% |
| 2022 FY | -145.03 Million SEK | 7.86% |
| 2022 Q4 | -83.56 Million SEK | -2016.62% |
| 2022 Q2 | -16.66 Million SEK | 59.21% |
| 2022 Q1 | -40.85 Million SEK | 13.31% |
| 2021 Q3 | -36.13 Million SEK | 26.65% |
| 2021 Q1 | -23.44 Million SEK | 49.16% |
| 2021 Q2 | -49.26 Million SEK | -110.11% |
| 2021 FY | -157.39 Million SEK | -6.75% |
| 2021 Q4 | -47.12 Million SEK | -30.44% |
| 2020 FY | -147.45 Million SEK | -28.75% |
| 2020 Q1 | -27.75 Million SEK | 14.91% |
| 2020 Q2 | -34.09 Million SEK | -22.87% |
| 2020 Q4 | -46.11 Million SEK | -21.16% |
| 2020 Q3 | -38.06 Million SEK | -11.63% |
| 2019 Q2 | -29.89 Million SEK | -13.31% |
| 2019 Q4 | -32.61 Million SEK | -27.28% |
| 2019 Q1 | -26.38 Million SEK | -2.84% |
| 2019 FY | -114.52 Million SEK | -32.34% |
| 2019 Q3 | -25.62 Million SEK | 14.29% |
| 2018 FY | -86.53 Million SEK | -91.32% |
| 2018 Q4 | -25.65 Million SEK | -47.42% |
| 2018 Q3 | -17.4 Million SEK | 33.46% |
| 2018 Q1 | -17.32 Million SEK | -13.11% |
| 2018 Q2 | -26.15 Million SEK | -50.95% |
| 2017 Q1 | -7.77 Million SEK | -44.52% |
| 2017 FY | -45.23 Million SEK | -207.22% |
| 2017 Q4 | -15.31 Million SEK | -32.18% |
| 2017 Q3 | -11.58 Million SEK | -9.81% |
| 2017 Q2 | -10.55 Million SEK | -35.81% |
| 2016 Q3 | -4.04 Million SEK | -39.97% |
| 2016 Q4 | -5.37 Million SEK | -32.84% |
| 2016 FY | -14.72 Million SEK | -99.4% |
| 2016 Q2 | -2.89 Million SEK | -20.2% |
| 2016 Q1 | -2.4 Million SEK | -34.54% |
| 2015 FY | -7.38 Million SEK | 16.65% |
| 2015 Q4 | -1.78 Million SEK | 0.0% |
| 2015 Q1 | -1.9 Million SEK | 36.79% |
| 2015 Q3 | -1.78 Million SEK | 6.05% |
| 2015 Q2 | -1.9 Million SEK | 0.0% |
| 2014 Q4 | -3.01 Million SEK | 0.0% |
| 2014 Q1 | -1.41 Million SEK | 0.0% |
| 2014 Q2 | -1.41 Million SEK | 0.0% |
| 2014 Q3 | -3.01 Million SEK | -112.39% |
| 2014 FY | -8.85 Million SEK | -454.94% |
| 2013 FY | -1.59 Million SEK | -516.6% |
| 2012 FY | -258.9 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AroCell AB (publ) | -59.29 Million SEK | -421.846% |
| Devyser Diagnostics AB (publ) | -53.6 Million SEK | -477.312% |
| Prostatype Genomics AB (publ) | -41.43 Million SEK | -646.806% |
| SenzaGen AB | -22.09 Million SEK | -1300.367% |
| Spermosens AB | -12.2 Million SEK | -2435.97% |